Search Results

In this episode of Denatured, BioSpace’s Head of Insights Lori Ellis, Miguel Forte and Ali Pashazadeh discuss how a slow and steady pace is a continuation of the pattern we have seen throughout the last three years.

Pattern Bioscience, Inc., an innovator in rapid diagnosis and antibiotic susceptibility testing for bacterial infections, announced the appointments of Tim Skansi as Chief Financial Officer and Travis Davies as Vice President of Operations.

Pattern Computer®, Inc. (“Pattern” or “the Company”) today announced the availability of the first paper produced by a research collaboration with Lawrence Berkeley National Laboratory (LBNL) and Los Alamos National Laboratory (LANL) and funded by the U.S. Department of Energy and the Defense Threat Reduction Agency (DTRA), which addresses the clear and critical need for pathogen agnostic diagnostics that can be quickly and effectively performed at point of need.

Pattern Computer®, Inc. (“Pattern” or “the Company”) today announced that Mark R. Anderson, Chairman and CEO, will participate in the 23rd Annual Needham Virtual Healthcare Conference, taking place April 8 – 11, 2024.

Pattern Computer®, Inc. announced at the Bio International Conference in San Diego that it is filing provisional patent applications with the United States Patent Office which covers 14 insilico discoveries in the form of potentially synergistic drug combinations for metastatic castrate resistant prostate cancer.

Pattern Bioscience, Inc. today announced that it was named the winner of the Disruptive Technology Award from the Association for Diagnostics & Laboratory Medicine (ADLM, formerly known as AACC).

Pattern Computer®, Inc. proudly announces the initiation of synergy and efficacy testing for two promising drug combinations identified within its High-Grade Serous Ovarian Cancer program.

Pattern Bioscience, Inc. today announced the completion of a $28.7 million Series C financing.

Staff cuts could leave IGM Biosciences with fewer than 55 employees. The company is also halting development of two bispecific antibody T cell engagers for autoimmune diseases.